에 대한 최신 뉴스 Nutex Health (NASDAQ:NUTX) 주식

Nutex Health

Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.

Market Recovery image

Opinion

Trading Ideas

ACHR

HNRG

NUTX

RGTI

RKLB

VNET

오늘은 유망한 기술적 추세가 주가 상승을 이끌고 있는 6가지 종목을 살펴보려고 한다. 벤징가 엣지에서 모멘텀 점수가 최소 98점 이상인 종목 중 향후 몇 주 동안 상승할 가능성이 있는 종목에 초점을 맞추고 있다.

미국 증시 반등 속 기술적 모멘텀 보이는 주식 6종목

Nutex Health Inc

Telsey Advisory Group analyst Dana Telsey maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Market Perform and maintains $24 price target.

News

Price Target

Analyst Ratings

VSCO

Telsey Advisory Group Maintains Market Perform on Victoria's Secret, Maintains $24 Price Target

WIIM

REVG

REV Group shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance.

Competitive statewide RFP win provides a platform for efficient expansion within the state
TEL AVIV, Israel, June 4, 2025 /PRNewswire/ -- SuperCom (NASDAQ:&nbsp;SPCB),&nbsp;a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, announced today that it has been awarded a statewide technology procurement contract by the North Carolina Sheriff's Association, emerging as the only new electronic monitoring technology provider selected through this competitive RFP. This contract serves as a procurement vehicle to allow all counties in North Carolina to contract directly with SuperCom on preset terms, most of the time without an additional RFP process. This strategic win is another testament to the Company's rapid expansion across the North American public safety market.

Contracts

SPCB

SuperCom Wins Statewide Technology Procurement Contract With North Carolina Sheriff's Association As Sole New Electronic Monitoring Provider

YEXT

Yext shares are trading higher after the company raised its FY26 adjusted EPS guidance above estimates. Also, Needham reiterated a Buy rating on the stock.

Telsey Advisory Group analyst Dana Telsey maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Market Perform and maintains $24 price target.

SHOO

Telsey Advisory Group Maintains Market Perform on Steven Madden, Maintains $24 Price Target

JFIN

Jiayin Group shares are trading higher after the company reported a year-over-year increase in its Q1 financial results.

Keybanc analyst Bradley Thomas reiterates Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) with a Overweight and maintains $135 price target.

Reiteration

OLLI

Keybanc Reiterates Overweight on Ollie's Bargain Outlet, Maintains $135 Price Target

Thor Industries shares are trading higher after the company reported better-than-expected Q3 financial results.

Telsey Advisory Group analyst Joseph Feldman maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Market Perform and maintains $95 price target.

DLTR

Telsey Advisory Group Maintains Market Perform on Dollar Tree, Maintains $95 Price Target

Keybanc analyst Bradley Thomas reiterates Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) from Sector Weight to Sector Weight.

Keybanc Reiterates Sector Weight on Dollar Generalto Sector Weight

MRUS

Merus shares are trading lower following its $300 million public offering announcement.

LITE

Lumentum Holdings shares are trading higher after the company raised its Q4 guidance. Additionally, Rosenblatt raised its price target on the stock from $94 to $105.

UBS analyst Karl Keirstead upgrades Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Neutral to Buy and raises the price target from $210 to $265.

Upgrades

SNOW

UBS Upgrades Snowflake to Buy, Raises Price Target to $265

ASAN

Asana shares are trading lower after the company issued FY26 guidance below estimates.

UBS analyst Anojja Shah initiates coverage on Sonoco Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>) with a Neutral rating and announces Price Target of $48.

Initiation

UBS Initiates Coverage On Sonoco Prods with Neutral Rating, Announces Price Target of $48

Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy
Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement in OS and Progression Free Survival ("PFS")
Clinical Benefit Rate ("CBR") was 59.4% (n=32), comprised of 18 subjects with stable disease and 1 subject with a partial response
Potential to address 13,500 new incidents of STS each year and market opportunity expected to grow to $2.6B by 20301
On-demand video webcast with members of the Moleculin management team and internationally renowned Key Opinion Leaders available Thursday, June 5th
HOUSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today reported positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases ("STS lung mets") (MB-107).
The MB-107 trial was a multi-center, open-label, single-arm monotherapy study that in Phase 1B determined the Maximum Tolerable Dose and Recommended Phase 2 Dose ("MTD", "RP2D" respectively) and safety of Annamycin and in Phase 2 explored the efficacy of Annamycin as a single agent for the treatment of subjects with STS lung mets for which chemotherapy was considered appropriate. For more information about the MB-107 trial visit <a href="https://www.globenewswire.com/Tracker?data=cIErFT_tsX39yiMPB49nWwCQtr1tUxq6RYQrO1PLLkBoMcgRmngECF7Tli-kjopu1eRuZxphaaV2VvIK4ZyejqFdWESfDHBbuhsXHq9zly4=">clinicaltrials.gov</a> and reference identifier NCT04887298.

Biotech

General

MBRX

Moleculin Biotech Reports Phase 1B/2 Trial Results For Annamycin In Soft Tissue Sarcoma Lung Metastases, Showing Efficacy As 7th Line Monotherapy With 59.4% Clinical Benefit Rate, Improved Overall And Progression-Free Survival

Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) is <a target="_blank" href="https://www.benzinga.com/topic/rivian" rel="noreferrer noopener">revamping the charging</a> experience for its electric vehicle customers.
The EV maker is launching a software update to its vehicles and smartphone app, offering more transparency about energy consumption and faster charging speeds, the Verge <a target="_blank" href="https://www.theverge.com/news/678005/rivian-ev-charging-software-update-battery-fast-charging" rel="noreferrer noopener">reported</a> on Tuesday.
Rivian&#8217;s Energy app will now include &#8220;Charging&#8221; for energy intake and &#8220;Energy Monitor&#8221; for energy output.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44934176/rivian-taps-ai-expert-aidan-gomez-to-drive-innovation-advanced-technology-integration" rel="noreferrer noopener">Tesla Rival Rivian Taps AI Expert Aidan Gomez To Drive Innovation</a>
The Charging tab shows a detailed breakdown of where the energy is going, including the battery and any connected accessories.
The Energy Monitor tab contains a new chart detailing how climate, outlets, and drive systems consume energy.
A new &#8220;Trip Target&#8221; feature provides charging recommendations when using navigation for a trip involving a charging stop to notify customers when they need to charge for the rest of the journey. 
Rivian is also adding a feature to precondition the battery on demand. The company obtained faster DC charging via a software update for its first- and second-generation EVs by optimizing battery temperatures in simulation.
Wassym Bensaid, Rivian&#8217;s chief software officer, told the Verge that it will roll out a new &#8220;Smart Charging&#8221; feature in July that allows customers to time their home-charging sessions.
In 2025, Rivian will launch a new bidirectional charging feature that enables users to utilize their vehicles as mobile power generators to send power to electronic devices.
Rivian stock surged over 28% in the last 12 months despite challenges associated with public EV charging, federal spending on charging installations, and the Trump administration&#8217;s tariff policies.
Despite mounting concerns over global trade tensions and tariffs, the company <a href="https://www.benzinga.com/markets/equities/25/05/45243985/rivian-holds-firm-on-45k-r2-price-despite-tariff-pressures-ceo-rj-scaringe-says-its-important-for-us-as-ev-maker-tops-q1-estimates" target="_blank" rel="noreferrer noopener">remains committed to</a> the $45,000 starting price for the upcoming R2 electric vehicle. It expects per-unit tariff impacts of approximately $2,000 for 2025.
Price Action:&nbsp;Rivian shares are trading higher by 0.97% at $14.51 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45745834/nio-stock-drops-after-q1-results-and-outlook-disappoints-the-street-margins-shrink" target="_blank" rel="noreferrer noopener">Nio Stock Drops After Q1 Results And Outlook Disappoints The Street, Margins Shrink</a></li>
</ul>
Photo: Shutterstock

RIVN

Rivian EVs Just Got Smarter: New App Tracks Energy Use And Speeds Up Charging

Hewlett Packard shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guidance.

UBS analyst Anojja Shah initiates coverage on Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) with a Neutral rating and announces Price Target of $200.

UBS Initiates Coverage On Packaging Corp of America with Neutral Rating, Announces Price Target of $200

Clear signs of a slowing labor market echoed through Wall Street on Wednesday, after private-sector job growth plunged to a more than two-year low, stoking investor concerns that trade headwinds are starting to bite while fueling President Donald Trump&#8216;s pressure on the Federal Reserve <a href="https://www.benzinga.com/news/econ-s">to lower interest rates. </a>
U.S. private employers added just 37,000 jobs in May, down from 62,000 in April, an Automatic Data Processing Inc. National Employment report showed Wednesday.
The outcome sharply missed economists&#8217; expectations of 115,000 and marked the lowest reading since March 2023. 
&#8220;ADP number out!!! &#8220;Too Late&#8221; Powell must now lower the rate. He is unbelievable!!! Europe has lowered nine times!,&#8221; Trump wrote on Truth social, shortly after the release.
"After a strong start to the year, hiring is losing momentum," said Nela Richardson, chief economist at Automatic Data Processing Inc. "Pay growth, however, was little changed in May, holding at robust levels for both job-stayers and job-changers."
In May, workers who stayed in their roles saw year-over-year wage growth of 4.5%, a steady pace from previous months. Those who changed jobs saw pay rise by 7%, also unchanged from April's revised figure.
While ADP's figures often differ from the official government data, the weak print adds weight to expectations of a broader labor market slowdown. The Bureau of Labor Statistics will publish its May Employment Situation Report on Friday, with nonfarm payrolls expected to rise by 130,000—down from April's 170,000 gain.
<h3 class="wp-block-heading">Market Reactions</h3>
The dollar tanked minutes after the release, with the greenback sliding past 1.14 against the euro. The Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – which tracks the broader U.S. dollar index (DXY) – is down 0.5% in the premarket. 
Futures on major U.S. indices were broadly steady by 8:25 a.m. in New York. On Tuesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) closed 0.6% higher. 
Yields on 2-year U.S. Treasury notes dropped to 3.92% as traders ramped up bets on upcoming Federal Reserve rate cuts. The 10-year yield also slipped, falling 5 basis points to 4.41%.
Fed funds futures now imply two interest rate cuts by the end of the year, with the first move expected to come in October, as per CME FedWatch tool.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45758298/april-inflation-print-was-the-last-vestige-of-pre-tariff-impact-feds-goolsbee-says">April Inflation Print Was The &#8216;Last Vestige&#8217; Of Pre-Tariff Impact, Fed&#8217;s Goolsbee Says </a></li>
</ul>
 Photo: Shutterstock

Econ #s

US Private Sector Hiring Slows The Most In 2 Years: 'Powell Must Now Lower The Rate,' Trump Says

Press Releases

Nutex Health Hospitals Earn Multiple Community Honors and Awards in Q4

Nutex Health Issues No Surprises Act (NSA) Arbitration Update

NUTEX HEALTH SCHEDULES 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS RELEASE AND CONFERENCE CALL

Nutex Health to Present at the EDPMA Solutions Summit 2025

NUTEX HEALTH RESCHEDULES EARNINGS RELEASE AND CONFERENCE CALL

Earnings

NUTEX HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

Nutex Health Schedules 2025 First Quarter Financial Results Release and Conference Call

Entertainment

Small Cap

NUTEX HEALTH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF GRANT THORNTON LLP AS ITS INDEPENDENT AUDITOR

NUTEX HEALTH ANNOUNCES INTERNET AVAILABILITY OF PROXY MATERIALS FOR ITS 2025 ANNUAL MEETING

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

Castle Biosciences

DocGo

Enhabit

Fulgent Genetics

InnovAge Holding

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

Kindly MD

NeoGenomics

National Research Corporation - Common Stock

National Research

OPKO Health

Performant Healthcare, Inc. - Common Stock

Performant Healthcare

Premier

Pennant Gr

Privia Health Gr

Talkspace

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Holdings

Maxim Group

Benchmark

<a href="https://www.benzinga.com/government/regulations/25/04/45015276/wall-street-rally-pauses-tesla-heads-for-strongest-week-in-6-months-whats-driving-markets-friday" target="_blank" rel="noopener">지난주</a> 시장은 월요일(21일)의 우려스러운 하락 이후 랠리를 시도했다. 금요일(25일) S&amp;P 500 지수는 도널드 트럼프 대통령이 상호관세 부과를 <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty" target="_blank" rel="noopener">90일간 유예한다고 발표</a>한 이후 처음으로 5,500포인트 이상으로 마감했다.
벤치마크 S&amp;P 500 지수는 여전히 관세 발표 전 수준보다 150포인트 낮았지만, 투자자들은 가장 가파른 수입세가 인하되거나 완전히 무효화될 것이라는 확신을 얻고 있다.
이번 주의 불안한 출발을 감안할 때 약세장이 끝났다고 말하기에는 아직 이르다. 하지만 단기 모멘텀이 형성되고 있는 종목을 찾기 시작하기에 좋은 시기로 보인다.
오늘은 유망한 기술적 추세가 주가 상승을 이끌고 있는 6가지 종목을 살펴보려고 한다. 벤징가 엣지에서 모멘텀 점수가 최소 98점 이상인 종목 중 향후 몇 주 동안 상승할 가능성이 있는 종목에 초점을 맞추고 있다.
<h3 class="wp-block-heading">리제티 컴퓨팅 (Rigetti Computing Inc.)</h3>
벤징가 엣지 모멘텀 점수: 99.86
양자 컴퓨팅 주식은 2025년의 첫 주요 투자 트렌드 중 하나였으며, 리제티 컴퓨팅(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>)은 양자 컴퓨터와 초전도 프로세서를 제조하는 가장 저명한 수혜자 중 하나였다. 이 회사의 주가는 추수감사절 무렵 1.50달러 미만으로 거래되다가 1월 첫째 주에 주가가 20달러를 돌파하는 포물선 상승세를 보였다. 기하급수적인 랠리는 얼마 지나지 않아 사라졌지만, 주가는 여전히 추수감사절 이전 평균을 훨씬 상회하고 있으며 다음 상승을 위해 준비하고 있을 수 있다.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXe56O1M3JQtasNTb3WpvSiFw9pcXN0K8637FvovhUiDDeja3dnylTb7ZTfXUv8MqKCS_4vw8PP_eZWTXcFDMOVP5FercsbsgG5wAwgqx-I0mCkMosvYfOCKXVBLInT9hyEtdKAV?key=BFT1P88ZKYnvATe0GLA-uBhm" alt="" /></figure>
리제티 주가는 3월 초부터 좁은 박스권에서 거래되었으며, 7.50달러 수준에서 지지선을 찾은 것으로 보이며 이중 바닥이 형성될 가능성이 있다. 또 다른 단기 강세 신호는 지수이동평균(EMA)으로, 단순이동평균(SMA)보다 최근 가격을 더 중시하는 지수이동평균에서 나온다. 지난 주 5일 EMA가 10일을 넘어섰고 이후 주가는 4일 연속 상승했다. 리제티는 5월 8일에 실적을 발표할 예정인데, 이는 이미 상승 추세의 기술적 신호를 보이고 있는 주식에 또 다른 촉매제가 될 수 있다.
<h3 class="wp-block-heading">뉴텍스 헬스(Nutex Health Inc.)</h3>
벤징가 엣지 모멘텀 점수: 99.94
뉴텍스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>)는 소규모 병원 및 외래 환자 센터와 같은 의료 시설을 소유하고 있는 소규모 의료 서비스 회사다. 또한 청구, 인사, 회계 및 법률을 위한 클라우드 기반 서비스를 제공한다. 뉴텍스 주가는 4월 초에 분기 매출이 2억 5,700만 달러로 200% 이상의 어닝 서프라이즈를 기록했다는 깜짝 실적 발표 이후 수년 만에 최고치로 치솟았다.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXclVzIbQdIn5Axi1ozMV6mi-C491wLKfxoi0hHHSSiAefuv8GmPqC7Hfkw3-2OwF3hzaColAPeKHXkrwIAoJtt32G16RnXRSgm3sek_CEfx1xFh13suTv1OtichKW1dlIEg9p8y4g?key=BFT1P88ZKYnvATe0GLA-uBhm" alt="" /></figure>
뉴텍스 주가는 이 돌파 이전부터 유망한 신호를 보였다. 50일 이평선이 9월에 200일 이평선을 넘어섰고, 이는 골든 크로스로 알려져 있으며 이후 주가의 지지선 역할을 해왔다. 그러나 주가는 빠르게 과매수되었고 상대강도지수(RSI)의 매도 신호와 함께 수일 연속 하락세를 보였다. 그러나 상승 추세는 여전히 유지되고 있으며 RSI는 과매수 트리거 지점인 70 아래로 돌아갔다. 50일 SMA가 과거 지지선 역할을 했던 것을 기억하며 이를 주시하자.
<h3 class="wp-block-heading">로켓랩 USA(Rocket Lab USA Inc.)</h3>
벤징가 엣지 모멘텀 점수: 99.46
로켓랩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)은 뉴트론(Neutron) 및 일렉트론(Electron) 발사체와 프로톤(Photon) 위성 시스템이라는 세 가지 제품군을 통해 우주선을 제작하고 발사한다. 로켓랩은 민간 및 상업용 서비스를 제공하며 여러 물체를 궤도에 올려놓았다. 주가는 10월에 수년간의 박스권에서 벗어나 1월에 사상 최고치를 경신하며 3개월 만에 200% 이상의 상승률을 달성했다.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXcc_nDaxh2ONdoH7w47EIXu0Eqz2ob_EYCEartuib7DtFw0jKjWVcRVX6gfClq8gCO2odgRq3rMdCRsF10mGfpdFbs8oNLHPFYEP6bByXINpLhMbpuDZHWroOEcljeV9k6DZSdNIA?key=BFT1P88ZKYnvATe0GLA-uBhm" alt="" /></figure>
그러나 로켓랩 주가는 2025년에도 주당 20달러 아래로 떨어지며 좁은 박스권에서 약세를 보였다. 주가는 2월에 50일 이평선 아래로 떨어졌지만 최근 두 달 만에 50일 이평선을 돌파하며 모멘텀을 되찾았다. RSI는 과매수 임계치 아래에 머물러 있어 이 돌파가 앞으로 강세를 보일 수 있음을 나타낸다.
<h3 class="wp-block-heading">브이넷 그룹 (VNet Group Inc.)</h3>
벤징가 엣지 모멘텀 점수: 98.58
브이넷 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>)은 는 베이징과 상하이 지역에 데이터 센터를 운영하고 있으며 알리바바, 텐센트와 같은 유명 기업을 고객으로 보유하고 있다. 로켓랩과 마찬가지로 브이넷의 주가는 올해 초 포물선을 그리며 폭등했다가 다시 하락했다. 주가는 15.34달러까지 올랐다가 이달 초 다시 5달러 아래로 떨어졌다.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXdCPwVUxMm9-TxlGnv_zAiMpcbcbf8C3wID2nu_pYphfsXKqMuxPL8gLVgWuZrjGVRTlT3-nLBaZgbXMUr-boP4Bby_ipGA1karSutrStrTJS0YTFha7NzZf_cNKvzornxqWzq_?key=BFT1P88ZKYnvATe0GLA-uBhm" alt="" /></figure>
하지만 기술적 신호가 반전을 가리키고 있기 때문에 이러한 매도세는 과도할 수 있다. RSI는 4월 들어 여러 차례 30 아래로 하락하며 과매도 상태를 나타낸다. 또한 주가는 5일 및 10일 이평선 아래에서 거래되었지만 이 두 수치 사이의 격차가 좁혀지고 있으며 현재 주가는 5일 이평선을 상회하고 있다. 5일 이평선이 10일 이평선 위로 교차하면 또 다른 상승 신호가 발생하며, 2개월간의 하락 추세가 빠르게 반전될 수 있다.
<h3 class="wp-block-heading">할라도르 에너지 (Hallador Energy Co.)</h3>
벤징가 엣지 모멘텀 점수: 98.40
인디애나에서 석탄을 채굴하는 할라도르 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>)를 예로 들어 5일 EMA가 10일 EMA를 돌파한 후 상승한 사례를 살펴볼 수 있다. 할라도르는 트럼프 행정부의 석탄에 대한 새로운 관심으로 순풍을 맞고 있으며, 주가 상승을 가리키는 몇 가지 기술적 패턴도 있다.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXd38x_XWW-XIPvF_Xynv-k2JtCVRWfoZ_CqOcx743I0aXv6o0vElzNsDsKAY-OwI9qVXh-Ls8e3MerzGRcQmtXbt2KC1bbq6saNL5pvblzoUAFi4ucDida6g5DnWyUouXeCdihl?key=BFT1P88ZKYnvATe0GLA-uBhm" alt="" /></figure>
주가는 지난 3개월 동안 이미 50% 이상 올랐고, 5일/10일 EMA 교차는 3주 만에 주가를 11달러에서 14.69달러로 끌어올리며 또 다른 대규모 녹색 캔들을 예고했다. 주가는 5일 및 10일 이평선 위에서 거래되고 있고 RSI는 아직 과매수 영역에 있지 않기 때문에 강세 모멘텀은 여전히 유지되고 있다.
<h3 class="wp-block-heading">아처 에비에이션 (Archer Aviation Inc.)</h3>
벤징가 엣지 모멘텀 점수: 98.61
아처 에비에이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>)은 최근 두 달 만에 3.21달러에서 11.51달러로 급등했다가 이달 초 다시 7달러 이하로 떨어지는 등 격동의 시기를 보냈다. 목록에 있는 대부분의 주식과 마찬가지로 아처 주가는 최근 상당한 상승 추세가 멈췄고 이제 턴어라운드 조짐을 보이고 있다.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXd925p-JDONF6Q-L1JYUVOTTHsM2qifLuhVsLGChjiK1fIlc8FXN4U2Z_pbQLZPFovxyga52hs2rT2-5qprLq0ZL5SBThsy1HuyJlfMU9aK-XDsKjZLftvQq_VZwaDv2OKdk_NV1A?key=BFT1P88ZKYnvATe0GLA-uBhm" alt="" /></figure>
아처 주가는 몇 주 동안 하락세를 보였으나 최근 2월 중순부터 이어진 하락 추세선을 돌파하며 침체에서 벗어났다. 상승 크로스오버는 MACD에서 이 돌파를 동반했으며, 이는 이 돌파가 합법적이라는 것을 뒷받침한다. 이러한 움직임의 잠재적 촉매제는 4월 21일 니덤의 매수 의견 재확인이며, 목표주가는 13달러로 51% 이상 상승 여력을 나타냈다.
&#x2A;전문가 기고자의 콘텐츠는 일반 대중을 위한 정보로, 개별화된 투자 조언이 아닙니다. 편집자/기고자는 개인적인 의견과 전략을 제시하며, 벤징가는 이에 대해 명시적이거나 묵시적으로 승인하거나 지지하지 않습니다.
사진: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Nutex Health

뉴스

에 대한 최신 뉴스 Nutex Health (NASDAQ:NUTX) 주식

수요일, 4월 30, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌